Clinical trials: Cancer: Solid Tumors
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of sirolimus and gold sodium thiomalate when given together in treating patients with advanced squamous non-small cell lung cancer (NSCLC).
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT01383668
- Testing
- sirolimus, gold sodium thiomalate, pharmacological study
- Sponsor
- Mayo Clinic
Cutaneous Melanoma, Pleural Mesothelioma
A Study of SGN-CD228A in Advanced Solid Tumors
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer
- Trial name
- NCT04042480
- Testing
- SGN-CD228A
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 88 people
- Sponsor
- Seagen Inc.
CANCER, NOS
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced…
- Trial name
- NCT01750580
- Testing
- Lirilumab, Ipilimumab
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Ovarian Cancer
LDE225 and Paclitaxel in Solid Tumors
The primary aim of this trial is to establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of LDE225 given in combination with standard doses of paclitaxel in patients with advanced solid tumors.
- Trial name
- NCT01954355
- Testing
- LDE225, Paclitaxel
- Where
- 4 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Swiss Cancer Institute
Pancreas Cyst, Pancreas Mass
RNA Sequencing of Solid and Cystic Lesions of the Pancreas
The nature of cysts and solid masses in the pancreas can be difficult to diagnose. They may be benign, precancerous, or cancer. Current tests such as cytology (looking under a microscope) and tumor markers do not always give us…
- Trial name
- NCT01807325
- Testing
- pancreas biopsy
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Oregon Health and Science University
Tumor, Solid, Lymphoma
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
This is a Phase I clinical study for evaluating the safety, pharmacokinetics, and preliminary efficacy of repeated doses, dose escalation of GR1405 injection in patients with advanced solid tumor or lymphoma
- Trial name
- NCT03731390
- Testing
- GR1405 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Treatment, Neoantigen
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
This is a clinical study of personalized self-DC vaccine targeting neo-antigen (Neo-DC vaccine) in the treatment of advanced solid tumors.
- Conditions
- Treatment, Neoantigen, Vaccine, Solid Tumor Cancer
- Trial name
- Neo-DCV-001 (NCT06682117)
- Testing
- DC Vaccine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Fudan University
Refractory Solid Tumors, Leukemia
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia.
- Trial name
- NCT00665990
- Testing
- Bevacizumab, Sorafenib, Cyclophosphamide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- St. Jude Children's Research Hospital
Refractory or Recurrent Solid Tumor
Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
Immunotherapies have revolutionized medical oncology following the remarkable and, in some cases, unprecedented outcomes observed in certain groups of patients with cancer.
- Trial name
- SPARTO (NCT05210413)
- Testing
- Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort, Spartalizumab in Adult cohort
- Where
- 13 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Bordeaux
Advanced Solid Tumors
Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)
This is a Phase I/II multicenter, first-in-human open-label, dose escalation study to evaluate the safety, tolerability, and anti-tumor activity of intratumoral (IT)/intralesional (IL) injections of MK-4621 (RGT100) in adult…
- Trial name
- NCT03065023
- Testing
- MK-4621
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
KRAS G12D, T Cell Therapy
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors
At present, there is an urgent need for new drugs for KRAS mutant tumors in clinic. Preclinical studies support the specificity, safety and anti-tumor activity of RE002.
- Trial name
- NCT06546150
- Testing
- RE002 T cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Adult Intracranial Tumor, Adult Solid Tumor
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
This will be a randomized blinded clinical trial. Patients will be randomized to receive either a remifentanil or dexmedetomidine infusion for general anesthesia.
- Trial name
- RemivsDex (NCT01269918)
- Testing
- Remifentanil, Dexmedetomidine
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- The Cleveland Clinic
Metastatic Solid Tumors
Phase I/Ib Multiple Ascending Dose Study in China
The purpose of this study was to evaluate the maximum tolerated dose (MTD) and pharmacokinetics (PK) of Avelumab monotherapy in Chinese subjects.
- Trial name
- NCT03523390
- Testing
- Avelumab 3 mg/kg Q2W, Avelumab 10 mg/kg Q2W, Avelumab 20 mg/kg Q2W
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery
RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery. PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with…
- Trial name
- NCT00096590
- Testing
- coagulation study, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cancer
Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
This is an intermediate patient expanded access protocol for treatment of patients with local or metastatic solid tumors with a neoantigen synthetic long peptide vaccine.
- Trial name
- NCT06963697
- Testing
- Personalized Synthetic Long Peptide Vaccine
- Where
- United States
- Sponsor
- Jaime Leandro Foundation for Therapeutic Cancer Vaccines
Unspecified Adult Solid Tumor, Protocol Specific
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002482
- Testing
- antibody therapy, biological therapy, muromonab-CD3
- Where
- United States
- Sponsor
- St. Vincent Medical Center - Los Angeles
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
This phase I study will determine the pharmacokinetic profile of patupilone in patients with mild or moderately impaired hepatic function within 2 cycles of treatment.
- Trial name
- NCT00420524
- Testing
- Patupilone/EPO906
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
A Study of SHR-1802 in Patients With Advanced Solid Tumor
To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in subjects with advanced solid tumor and to determine the dose-limiting toxicity (DLT)，recommended phase II dose (RP2D) and assess…
- Trial name
- NCT05208177
- Testing
- SHR-1802＋camrelizumab + famitinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in treating patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT00119236
- Testing
- tanespimycin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Tumors
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced…
- Trial name
- NCT00395434
- Testing
- Combretastatin A4 Phosphate (CA4P), Bevacizumab (Avastin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Mateon Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.